.png)
ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with bullous pemphigoid (BP), a phase 2/3 study demonstrated. “Dupilumab demonstrated significant benefits across multiple disease aspects in BP at 36 weeks...
Axis Mundi Systems LLC 3773 Howard Ave Las Vegas, NV
Toll Free: 877-749-7128 ext. 500
office@cruisewithbruce.com
Copyright © 2023 virtualluxurytravelnews. All Rights Reserved
